江苏恒瑞医药股份有限公司2025年第一季度报告

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., emphasizes the accuracy and completeness of its financial disclosures and announces an upcoming earnings presentation for Q1 2025 to engage with investors and address their concerns [1][7][8]. Financial Data - The financial report for Q1 2025 is unaudited, and the company confirms that there are no significant changes in the financial indicators compared to the previous period [2][6]. - The report includes a consolidated balance sheet and profit statement for the period from January to March 2025, with no net profit reported from merged entities [5][6]. Shareholder Information - The company has confirmed that there are no changes in the major shareholders or their holdings that would affect the financial report [4][5]. Investor Communication - An earnings presentation will be held on April 30, 2025, from 1:00 PM to 2:00 PM, via the Shanghai Stock Exchange Roadshow Center, allowing investors to ask questions and receive answers regarding the company's performance [8][10][11]. - Investors can submit questions until April 29, 2025, to ensure their concerns are addressed during the presentation [9][11].